Comparative efficacy of therapies for treatment of depression for patients undergoing maintenance hemodialysis

Rajnish Mehrotra, Daniel Cukor, Mark Unruh, Tessa Rue, Patrick Heagerty, Scott D. Cohen, Laura M. Dember, Yaminette Diaz-Linhart, Amelia Dubovsky, Tom Greene, Nancy Grote, Nancy Kutner, Madhukar H Trivedi, Davin K. Quinn, Nishaver Halen, Steven D. Weisbord, Bessie A. Young, Paul L. Kimmel, S S Hedayati

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Although depression is common among patients receiving maintenance hemodialysis, data on their acceptance of treatment and on the comparative efficacy of various therapies are limited. Objective: To determine the effect of an engagement interview on treatment acceptance (phase 1) and to compare the efficacy of cognitive behavioral therapy (CBT) versus sertraline (phase 2) for treating depression in patients receiving hemodialysis. Design: Multicenter, parallel-group, open-label, randomized controlled trial. (ClinicalTrials.gov: NCT02358343) Setting: 41 dialysis facilities in 3 U.S. metropolitan areas. Participants: Patients who had been receiving hemodialysis for at least 3 months and had a Beck Depression Inventory-II score of 15 or greater; 184 patients participated in phase 1, and 120 subsequently participated in phase 2. Intervention: Engagement interview versus control visit (phase 1) and 12 weeks of CBT delivered in the dialysis facility versus sertraline treatment (phase 2). Measurements: The primary outcome for phase 1 was the proportion of participants who started depression treatment within 28 days. For phase 2, the primary outcome was depressive symptoms measured by the Quick Inventory of Depressive Symptoms Clinician-Rated (QIDS-C) at 12 weeks. Results: The proportion of participants who initiated treatment after the engagement or control visit did not differ (66% vs. 64%, respectively; P = 0.77; estimated risk difference, 2.1 [95% CI, _12.1 to 16.4]). Compared with CBT, sertraline treatment resulted in lower QIDS-C depression scores at 12 weeks (effect estimate, _1.84 [CI, _3.54 to _0.13]; P = 0.035). Adverse events were more frequent in the sertraline than the CBT group. Limitation: No randomized comparison was made with no treatment, and persistence of treatment effect was not assessed. Conclusion: An engagement interview with patients receiving maintenance hemodialysis had no effect on their acceptance of treatment for depression. After 12 weeks of treatment, depression scores were modestly better with sertraline treatment than with CBT. Primary Funding Source: Patient-Centered Outcomes Research Institute, Dialysis Clinic, Kidney Research Institute, and National Institute of Diabetes and Digestive and Kidney Diseases.

Original languageEnglish (US)
Pages (from-to)369-379
Number of pages11
JournalAnnals of internal medicine
Volume170
Issue number6
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Renal Dialysis
Maintenance
Depression
Sertraline
Cognitive Therapy
Therapeutics
Dialysis
Interviews
Equipment and Supplies
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
Patient Outcome Assessment
Randomized Controlled Trials
Kidney

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Comparative efficacy of therapies for treatment of depression for patients undergoing maintenance hemodialysis. / Mehrotra, Rajnish; Cukor, Daniel; Unruh, Mark; Rue, Tessa; Heagerty, Patrick; Cohen, Scott D.; Dember, Laura M.; Diaz-Linhart, Yaminette; Dubovsky, Amelia; Greene, Tom; Grote, Nancy; Kutner, Nancy; Trivedi, Madhukar H; Quinn, Davin K.; Halen, Nishaver; Weisbord, Steven D.; Young, Bessie A.; Kimmel, Paul L.; Hedayati, S S.

In: Annals of internal medicine, Vol. 170, No. 6, 01.01.2019, p. 369-379.

Research output: Contribution to journalArticle

Mehrotra, R, Cukor, D, Unruh, M, Rue, T, Heagerty, P, Cohen, SD, Dember, LM, Diaz-Linhart, Y, Dubovsky, A, Greene, T, Grote, N, Kutner, N, Trivedi, MH, Quinn, DK, Halen, N, Weisbord, SD, Young, BA, Kimmel, PL & Hedayati, SS 2019, 'Comparative efficacy of therapies for treatment of depression for patients undergoing maintenance hemodialysis', Annals of internal medicine, vol. 170, no. 6, pp. 369-379. https://doi.org/10.1093/ndt/gfr778
Mehrotra, Rajnish ; Cukor, Daniel ; Unruh, Mark ; Rue, Tessa ; Heagerty, Patrick ; Cohen, Scott D. ; Dember, Laura M. ; Diaz-Linhart, Yaminette ; Dubovsky, Amelia ; Greene, Tom ; Grote, Nancy ; Kutner, Nancy ; Trivedi, Madhukar H ; Quinn, Davin K. ; Halen, Nishaver ; Weisbord, Steven D. ; Young, Bessie A. ; Kimmel, Paul L. ; Hedayati, S S. / Comparative efficacy of therapies for treatment of depression for patients undergoing maintenance hemodialysis. In: Annals of internal medicine. 2019 ; Vol. 170, No. 6. pp. 369-379.
@article{b0a30472abcb40d5b70a650033b430de,
title = "Comparative efficacy of therapies for treatment of depression for patients undergoing maintenance hemodialysis",
abstract = "Background: Although depression is common among patients receiving maintenance hemodialysis, data on their acceptance of treatment and on the comparative efficacy of various therapies are limited. Objective: To determine the effect of an engagement interview on treatment acceptance (phase 1) and to compare the efficacy of cognitive behavioral therapy (CBT) versus sertraline (phase 2) for treating depression in patients receiving hemodialysis. Design: Multicenter, parallel-group, open-label, randomized controlled trial. (ClinicalTrials.gov: NCT02358343) Setting: 41 dialysis facilities in 3 U.S. metropolitan areas. Participants: Patients who had been receiving hemodialysis for at least 3 months and had a Beck Depression Inventory-II score of 15 or greater; 184 patients participated in phase 1, and 120 subsequently participated in phase 2. Intervention: Engagement interview versus control visit (phase 1) and 12 weeks of CBT delivered in the dialysis facility versus sertraline treatment (phase 2). Measurements: The primary outcome for phase 1 was the proportion of participants who started depression treatment within 28 days. For phase 2, the primary outcome was depressive symptoms measured by the Quick Inventory of Depressive Symptoms Clinician-Rated (QIDS-C) at 12 weeks. Results: The proportion of participants who initiated treatment after the engagement or control visit did not differ (66{\%} vs. 64{\%}, respectively; P = 0.77; estimated risk difference, 2.1 [95{\%} CI, _12.1 to 16.4]). Compared with CBT, sertraline treatment resulted in lower QIDS-C depression scores at 12 weeks (effect estimate, _1.84 [CI, _3.54 to _0.13]; P = 0.035). Adverse events were more frequent in the sertraline than the CBT group. Limitation: No randomized comparison was made with no treatment, and persistence of treatment effect was not assessed. Conclusion: An engagement interview with patients receiving maintenance hemodialysis had no effect on their acceptance of treatment for depression. After 12 weeks of treatment, depression scores were modestly better with sertraline treatment than with CBT. Primary Funding Source: Patient-Centered Outcomes Research Institute, Dialysis Clinic, Kidney Research Institute, and National Institute of Diabetes and Digestive and Kidney Diseases.",
author = "Rajnish Mehrotra and Daniel Cukor and Mark Unruh and Tessa Rue and Patrick Heagerty and Cohen, {Scott D.} and Dember, {Laura M.} and Yaminette Diaz-Linhart and Amelia Dubovsky and Tom Greene and Nancy Grote and Nancy Kutner and Trivedi, {Madhukar H} and Quinn, {Davin K.} and Nishaver Halen and Weisbord, {Steven D.} and Young, {Bessie A.} and Kimmel, {Paul L.} and Hedayati, {S S}",
year = "2019",
month = "1",
day = "1",
doi = "10.1093/ndt/gfr778",
language = "English (US)",
volume = "170",
pages = "369--379",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "6",

}

TY - JOUR

T1 - Comparative efficacy of therapies for treatment of depression for patients undergoing maintenance hemodialysis

AU - Mehrotra, Rajnish

AU - Cukor, Daniel

AU - Unruh, Mark

AU - Rue, Tessa

AU - Heagerty, Patrick

AU - Cohen, Scott D.

AU - Dember, Laura M.

AU - Diaz-Linhart, Yaminette

AU - Dubovsky, Amelia

AU - Greene, Tom

AU - Grote, Nancy

AU - Kutner, Nancy

AU - Trivedi, Madhukar H

AU - Quinn, Davin K.

AU - Halen, Nishaver

AU - Weisbord, Steven D.

AU - Young, Bessie A.

AU - Kimmel, Paul L.

AU - Hedayati, S S

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Although depression is common among patients receiving maintenance hemodialysis, data on their acceptance of treatment and on the comparative efficacy of various therapies are limited. Objective: To determine the effect of an engagement interview on treatment acceptance (phase 1) and to compare the efficacy of cognitive behavioral therapy (CBT) versus sertraline (phase 2) for treating depression in patients receiving hemodialysis. Design: Multicenter, parallel-group, open-label, randomized controlled trial. (ClinicalTrials.gov: NCT02358343) Setting: 41 dialysis facilities in 3 U.S. metropolitan areas. Participants: Patients who had been receiving hemodialysis for at least 3 months and had a Beck Depression Inventory-II score of 15 or greater; 184 patients participated in phase 1, and 120 subsequently participated in phase 2. Intervention: Engagement interview versus control visit (phase 1) and 12 weeks of CBT delivered in the dialysis facility versus sertraline treatment (phase 2). Measurements: The primary outcome for phase 1 was the proportion of participants who started depression treatment within 28 days. For phase 2, the primary outcome was depressive symptoms measured by the Quick Inventory of Depressive Symptoms Clinician-Rated (QIDS-C) at 12 weeks. Results: The proportion of participants who initiated treatment after the engagement or control visit did not differ (66% vs. 64%, respectively; P = 0.77; estimated risk difference, 2.1 [95% CI, _12.1 to 16.4]). Compared with CBT, sertraline treatment resulted in lower QIDS-C depression scores at 12 weeks (effect estimate, _1.84 [CI, _3.54 to _0.13]; P = 0.035). Adverse events were more frequent in the sertraline than the CBT group. Limitation: No randomized comparison was made with no treatment, and persistence of treatment effect was not assessed. Conclusion: An engagement interview with patients receiving maintenance hemodialysis had no effect on their acceptance of treatment for depression. After 12 weeks of treatment, depression scores were modestly better with sertraline treatment than with CBT. Primary Funding Source: Patient-Centered Outcomes Research Institute, Dialysis Clinic, Kidney Research Institute, and National Institute of Diabetes and Digestive and Kidney Diseases.

AB - Background: Although depression is common among patients receiving maintenance hemodialysis, data on their acceptance of treatment and on the comparative efficacy of various therapies are limited. Objective: To determine the effect of an engagement interview on treatment acceptance (phase 1) and to compare the efficacy of cognitive behavioral therapy (CBT) versus sertraline (phase 2) for treating depression in patients receiving hemodialysis. Design: Multicenter, parallel-group, open-label, randomized controlled trial. (ClinicalTrials.gov: NCT02358343) Setting: 41 dialysis facilities in 3 U.S. metropolitan areas. Participants: Patients who had been receiving hemodialysis for at least 3 months and had a Beck Depression Inventory-II score of 15 or greater; 184 patients participated in phase 1, and 120 subsequently participated in phase 2. Intervention: Engagement interview versus control visit (phase 1) and 12 weeks of CBT delivered in the dialysis facility versus sertraline treatment (phase 2). Measurements: The primary outcome for phase 1 was the proportion of participants who started depression treatment within 28 days. For phase 2, the primary outcome was depressive symptoms measured by the Quick Inventory of Depressive Symptoms Clinician-Rated (QIDS-C) at 12 weeks. Results: The proportion of participants who initiated treatment after the engagement or control visit did not differ (66% vs. 64%, respectively; P = 0.77; estimated risk difference, 2.1 [95% CI, _12.1 to 16.4]). Compared with CBT, sertraline treatment resulted in lower QIDS-C depression scores at 12 weeks (effect estimate, _1.84 [CI, _3.54 to _0.13]; P = 0.035). Adverse events were more frequent in the sertraline than the CBT group. Limitation: No randomized comparison was made with no treatment, and persistence of treatment effect was not assessed. Conclusion: An engagement interview with patients receiving maintenance hemodialysis had no effect on their acceptance of treatment for depression. After 12 weeks of treatment, depression scores were modestly better with sertraline treatment than with CBT. Primary Funding Source: Patient-Centered Outcomes Research Institute, Dialysis Clinic, Kidney Research Institute, and National Institute of Diabetes and Digestive and Kidney Diseases.

UR - http://www.scopus.com/inward/record.url?scp=85063918614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063918614&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfr778

DO - 10.1093/ndt/gfr778

M3 - Article

C2 - 22273670

AN - SCOPUS:85063918614

VL - 170

SP - 369

EP - 379

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 6

ER -